Dr Reddy's Labs, Cipla facilities join World Economic Forum Global Lighthouse Network
On Cipla, the WEF said the company deployed digital, automation and analytics solutions to 22 Indian sites to preserve access to high-quality affordable drugs globally while facing an increase in material and labour costs.
New Delhi: The World Economic Forum on Tuesday announced the addition of 11 factories and industrial sites, including three from India, to its Global Lighthouse Network.
From India, the additions are pharma major Cipla's Indore facility, Dr Reddy's Laboratories' Hyderabad facility, and the Mondelez facility in Sri City.
The Global Lighthouse Network is a community of over 100 manufacturers that are showing leadership in applying Fourth Industrial Revolution technologies such as artificial intelligence, 3D-printing, and big data analytics.
The WEF further said four lighthouse members with outstanding environmental footprint reductions have been given an additional designation of Sustainability Lighthouses.
These four include Unilever's Dapada facility in India.
The WEF said that amid warnings of a global recession, energy price hikes, and disrupted supply chains, the lighthouse factories offer business leaders and policymakers examples of how the manufacturing sector can stay competitive and continue to create jobs.
"Manufacturing is the backbone of both social and economic development. With the right corporate strategies and industrial policies, it provides high-wage jobs, commercial innovation, and drives environmental sustainability – even in times of crisis," said Francisco Betti, Head of Advanced Manufacturing and Value Chains at the WEF.
The new factories of the lighthouse network show how manufacturers can meet business goals while having a positive impact on economies, people's livelihoods, and the environment, Betti added.
The 11 new lighthouses also include Agilent Technologies in Singapore, Danone in Opole (Poland), Flex in Sorocaba (Brazil), and five in China (CATL, Haier, Midea, Sany Heavy Industry, and Western Digital).
On Cipla, the WEF said the company deployed digital, automation, and analytics solutions to 22 Indian sites to preserve access to high-quality affordable drugs globally while facing an increase in material and labour costs.
The company's Oral Solid Dosage facility in Indore led this journey by implementing 30 Fourth Industrial Revolution use cases, thereby improving total cost by 26 percent and enhancing quality by 300 percent while reducing greenhouse gas (GHG) emissions by 28 percent.
For Dr Reddy's Hyderabad facility, the WEF said the 25-year-old site, facing business challenges from severe price erosion and rapidly evolving quality expectations, embarked on large-scale digitalisation to sustain and grow in the generics pharma market.
The site deployed more than 40 Fourth Industrial Revolution use cases by operating in garage mode and leveraging IIoT (industrial internet of things) and democratised platform for advanced analytics.
As a result, it improved manufacturing cost by 43 percent while proactively enhancing the quality and reducing energy by 41 percent.
Mondelez's Sri City facility deployed end-to-end digitalisation, predictive analytics, artificial intelligence, and advanced automations with an aim to outgrow the market through superior volume delivery, cost leadership and build further resilience and diversity in a volatile environment.
It managed to increase labour productivity by 89 percent, reduce manufacturing costs by 38 percent and sustain 50 percent female workforce, thus making it a benchmark manufacturing site for Mondelez globally, the WEF added.
Read also: LIC increases its stake in Dr Reddy's Laboratories from 5.65 percent to 7.7 percent
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd